Terminated PHASE1 INTERVENTIONAL 2-arm NCT01289938

Pharmacogenetic Factors and Side Effects of Metoclopramide and Diphenhydramine (MalD)

Sponsor: Matthias Schwab

Conditions Drug Metabolism, Poor, CYP2D6-RELATED

Interventions Diphenhydramine Metoclopramide

Updated 9 times since 2017 Last updated: May 12, 2016 Started: Jul 31, 2009 Primary completion: Jun 30, 2015 Completion: Jun 30, 2015

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Terminated

To unsuccessful recruitment of rare UM-genotype. All other planned genotype groups are completed (EM, IM and PM).

Other terminated trials from Matthias Schwab

Gastroesophageal Reflux · Phase PHASE4 · Dec 2010

More terminations from Matthias Schwab

A PHASE1 clinical study on Drug Metabolism, Poor, CYP2D6-RELATED, this trial is terminated or withdrawn. The trial is conducted by Matthias Schwab and has accumulated 9 data snapshots since 2009. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.

Status Flow

Change History

9 versions recorded

Sep 2024 — Present [monthly]

Terminated PHASE1
Jul 2024 — Sep 2024 [monthly]

Terminated PHASE1
Dec 2021 — Jul 2024 [monthly]

Terminated PHASE1
Jan 2021 — Dec 2021 [monthly]

Terminated PHASE1
Nov 2020 — Jan 2021 [monthly]

Terminated PHASE1

▶ Show 4 earlier versions

Jun 2018 — Nov 2020 [monthly]

Terminated PHASE1
May 2018 — Jun 2018 [monthly]

Terminated PHASE1
Aug 2017 — May 2018 [monthly]

Terminated PHASE1
Jan 2017 — Aug 2017 [monthly]

Terminated PHASE1

First recorded

Jul 2009

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Matthias Schwab

Data source: University Hospital Tuebingen

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Tübingen, Germany